RedHill Biopharma

Proprietary Drugs for Gastrointestinal and Infectious Diseases

Health Tech & Life Sciences
Public on NASDAQ on Jan 2012

Company Overview

Snapshot

Founded in August 2009 by Dror Ben-Asher, RedHill Biopharma operates with 11–50 employees. The company has raised a total of $307.15 million across 23 funding rounds and has received funding from 14 investors. In October 2025, RedHill's Talicia secured a $4 million strategic investment and a U.S. co-commercialization partnership deal.

Business overview

RedHill Biopharma is a specialty biopharmaceutical company focused on developing and commercializing proprietary drugs for gastrointestinal and infectious diseases. The company's core products include two FDA-approved drugs, Talicia and Aemcolo, which are promoted in the U.S. by a dedicated sales team. RedHill also maintains an advanced and de-risked R&D pipeline of late-stage clinical development drug candidates, addressing significant unmet medical needs within the pharmaceuticals and healthcare sectors.

Strategic signal

In September 2024, RedHill Biopharma's Talicia was listed as a first-line choice for H. pylori in the new American College of Gastroenterology guidelines. This endorsement signals strong clinical validation and market acceptance for Talicia, potentially driving increased adoption and revenue for RedHill within the gastroenterology market.

Company Intelligence Q&A

What was a significant recent commercial development for Talicia?
In October 2025, RedHill's Talicia secured a $4 million strategic investment and a U.S. co-commercialization partnership deal with Cumberland Pharmaceuticals Inc.
What recent regulatory milestone did Talicia achieve?
In September 2024, RedHill's Talicia was listed as a first-line choice for H. pylori in the new American College of Gastroenterology guidelines.
What was the outcome of the New York Supreme Court appeal for RedHill Biopharma?
In September 2025, the New York Supreme Court upheld its original summary judgment ruling in favor of RedHill, dismissing an appeal and upholding a $10 million summary judgment against Kukbo.
What is the latest update regarding RedHill's compliance with Nasdaq listing requirements?
In October 2025, RedHill Biopharma received a Nasdaq Staff Determination notification regarding continued non-compliance with the minimum bid price requirement.
What was a recent development for Opaganib related to U.S. government funding?
In October 2024, RedHill Biopharma secured U.S. government funding through BARDA to advance Opaganib for Ebola treatment.

External links